In fact, in Europe, the USA, and Australia, following the widespread introduction of the prostate-specific antigen (PSA) test, which allowed the detection of preclinical cancers, there have been rapid increases in prostate cancer incidence rates since the late 1980s/early 1990s [1]. The gene discussed is KLK3; the disease is cancer.